Analyst firms · Oppenheimer · BMRN

Oppenheimer BMRN price target and rating history

BioMarin Pharmaceutical Inc. (BMRN) · Health Care

Oppenheimer rates BioMarin Pharmaceutical Inc. (BMRN) Outperform with a $98 price target, as of its latest action on Feb 24, 2025. It has published 3 rating actions on BMRN since October 2022, including 2 upgrades and 1 downgrade. Across 9 firms with a BMRN price target in the last 12 months, the median target is $88.

Current rating
Outperform
Price target
$98
Median target, all firms
$88
Actions on BMRN
3

Oppenheimer price target on BMRN

$110$104$982023202420252026
Oppenheimer price target on BMRN, each point a stated target, October 2022 to February 2025.

Every Oppenheimer rating on BMRN

How other firms rate BMRN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$88Oct 15, 2026
Raymond JamesStrong Buy$109Oct 12, 2026
BMO Capital MarketsOutperform$98Aug 19, 2026
CitigroupBuy$75May 19, 2026
Goldman SachsNeutral$69May 11, 2026
Morgan StanleyOverweight$120Apr 27, 2026
BarclaysOverweight$80Jan 28, 2026
Canaccord GenuityBuy$98Jan 20, 2026
Leerink PartnersMarket Perform$60Dec 3, 2025

Questions about Oppenheimer and BMRN

What is Oppenheimer's price target for BMRN?
Oppenheimer's latest stated price target for BioMarin Pharmaceutical Inc. (BMRN) is $98, from its action on Feb 24, 2025.
What is Oppenheimer's rating on BMRN?
Oppenheimer rates BMRN Outperform, a bullish rating, as of Feb 24, 2025.
When did Oppenheimer last change its view on BMRN?
On Feb 24, 2025, Oppenheimer upgrades to Outperform from Perform, price target $98.
How does Oppenheimer's BMRN target compare with other analysts?
Across 9 firms with a BMRN price target in the last 12 months, the median target is $88.

More BMRN rating histories

All Oppenheimer ratingsBMRN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.